AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukemia
  • Age: Between 2 years - 21 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have newly diagnosed HR Ph-like B-ALL meeting any of the following:

          Patients ≥ 10 years at diagnosis

          WBC ≥ 50 X 10^3/µL

          CNS3 leukemia at diagnosis


    2.  Patients must have completed a 4-drug regimen Induction therapy


    3.  Patients should have eligible genetic alterations (please contact study PI for details)

You may not be eligible for this study if the following are true:

  • 1.  Receipt of any other cytotoxic chemotherapy before Induction therapy; prior treatment with a JAK inhibitor for any indication


    2.  Patients with BCR-ABL1-rearranged ALL


    3.  Patients with Trisomy 21; other malignancy in addition to ALL, or secondary ALL


    4.  Patients with chronic or current active infectious disease requiring systemic antibiotics, antifungal treatment, or antiviral treatment that is not well-controlled or resolving

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.